Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $457

أمجين

Amgen Inc.

AMGN

0.00

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ: AMGN) with a Overweight and raises the price target from $427 to $457.